Susceptibility of Mycobacterium tuberculosis strains to first-line and second-line antituberculosis drugs in Ege University Hospital

Basit Öğe Kaydı
dc.contributor.authorÇiçek Saydam C.
dc.contributor.authorÇavuşoglu C.
dc.contributor.authorBurhanoglu D.
dc.contributor.authorÖzkalay N.
dc.contributor.authorBadak F.Z.
dc.contributor.authorBilgiç A.
dc.date.accessioned2019-10-27T00:25:17Z
dc.date.available2019-10-27T00:25:17Z
dc.date.issued2001
dc.departmentEge Üniversitesien_US
dc.description.abstractRecently tuberculosis has shown a speedy worldwide spread. The incidence of drug-resistant Mycobacterium tuberculosis is increasing in almost all industrialized and developing countries. The epidemiology of multiple drug resistance varies in different regions and countries. The aim of this study was to determine the activities of first-line (isoniazid, rifampin, ethambutol and streptomycin) and second-line (kanamycin, para-aminosalicylic acid, ethionamide and capreomycin) antituberculosis drugs on 100 various clinical isolates of M. tuberculosis. Mycobacterium tuberculosis ATCC 27294, ATCC 35838, ATCC 35825 and ATCC 35837 were used for internal quality control. First-line drug resistant strains were isolated from 10 clinical specimens. Six of them showed resistance to a single drug and four to more than one first-line drug. All of the single-drug resistant strains were resistant to isoniazid. Of 100 isolates, 56 were resistant to capreomycin, 41 to kanamycin, 12 to para-aminosalicylic acid and four to ethionamide. All of the first-line drug-resistant strains were found to be susceptible to para-aminosalicylic acid and ethionamide. In view of the above findings, we suggest that clinicians should be well-informed about the current local epidemiology of tuberculosis, and health care institutions should maintain up-to-date drug susceptibility data on the local isolates of M. tuberculosis.en_US
dc.identifier.endpage400en_US
dc.identifier.issn1300-0144
dc.identifier.issue5en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage395en_US
dc.identifier.urihttps://hdl.handle.net/11454/23222
dc.identifier.volume31en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCapreomycinen_US
dc.subjectEthambutolen_US
dc.subjectEthionamideen_US
dc.subjectIsoniaziden_US
dc.subjectKanamycinen_US
dc.subjectMycobacterium tuberculosisen_US
dc.subjectPara-aminosalicylic aciden_US
dc.subjectRifampinen_US
dc.subjectStreptomycinen_US
dc.subjectSusceptibilityen_US
dc.titleSusceptibility of Mycobacterium tuberculosis strains to first-line and second-line antituberculosis drugs in Ege University Hospitalen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu